Ezrin pathway in cancer.

Ezrin pathway in cancer.

Ezrin Biosensor

Ezrin is a founding member of the ezrin-radixin-moesin (ERM) family of adaptor proteins. Ezrin is frequently over-expressed in invasive carcinoma cells and is associated with relapse and poor outcome in several solid cancers including breast, lung, osteosarcoma, colorectal, prostate, and pancreas. Biological functions for ezrin coupled with observations from preclinical models and association between expression and clinical outcomes strongly supports its relevance as both a biomarker and therapeutic target in breast cancer. We have developed an innovative ezrin biosensor to track ezrin function and perform high-throughput screening to discover novel inhibitors suitable for drug development.